References
- Abramczuk E., Pancer K., Gut W., Litwińska B.: Niepandemiczne koronawirusy człowieka – charakterystyka i diagnostyka. Post. Mikrob. 56, 205–213 (2017)
- Ahmed S.F., Quadeer A.A., McKay M.R.: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12, 254 (2020)
- Amanat F., Moran T. i wsp.: A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv, DOI: 10.1101/2020.03.17.20037717 (2020)
- AOTiM: Zalecenia w COVID-19, 25.04.2020, http://www.aotm.gov.pl/www/wp-content/uploads/covid_19/2020.04.25_zalecenia%20covid19_v1.1.pdf (7.06.2020)
- Bavishi C., Maddox T.M., Messerli F.H.: Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. DOI: 10.1001/jamacardio.2020.1282 (2020)
- Belouzard S., Millet J.K., Licitra B.N., Whittaker G.R.: Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 4, 1011–1033 (2012)
- Chen L., Xiong J., Bao L., Shi Y.: Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020)
- Chen N., Zhang L. i wsp.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395, 507–513 (2020)
- Chen Y., Peng H., Wang L., Zhao Y., Zeng L., Gao H., Liu Y.: Infants Born to Mothers With a New Coronavirus (COVID-19). Front. Pediatr. DOI: 10.3389/fped.2020.00104 (2020)
- ClinicalTrials.gov: Phase I Clinical Trial of a COVID-19 Vaccine in 18–60 Healthy Adults (CTCOVID-19), 19.05.2020, https://clinicaltrials.gov/ct2/show/NCT04313127 (07.06.2020)
- Clinical Trials.gov: Use of Ascorbic Acid in Patients With COVID-19, 26.03.2020, https://clinicaltrials.gov/ct2/show/NCT04323514 (08.06.2020)
- Danielsson N., Catchpole M.: Novel coronavirus associated with severe respiratory disease: Case definition and public health measure. Euro Surveill. DOI: 10.2807/ese.17.39.20282-en (2012)
- Day M.: COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ, DOI: 10.1136/bmj.m1086 (2020)
- Du L., He Y., Zhou Y., Liu S., Zheng B. J., Jiang S.: The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009)
- Du L., Li F. i wsp.: Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7, 13473 (2016)
- Eichler H.G., Cavaleri M., Enzmann H., Scotti F., Sepodes B., Sweeney F., Vamvakas S., Rasi G.: Clinical Trials for Covid-19: Can We Better Use the Short Window of Opportunity? Clin. Pharmacol. Ther. DOI: 10.1002/cpt.1891 (2020)
- Etemad B., Whitcomb D.C.: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology, 120, 682–707 (2001)
- European Respiratory Society: ACE2 receptor blocers: a novel therapeutic approach for COVID-19, 14.04.2020, https://www.ersnet.org/covid-19-blog/ace2-receptor-blockers-a-novel-the-rapeutic-approach-for-covid-19 (17.05.2020)
- Fang L., Karakiulakis G., Roth M.: Are Patients With Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? Lancet Respir. Med. DOI: 10.1016/S2213-2600(20)30116-8 (2020)
- Forbes: What Do Testicles Have To Do With COVID-19 Coronavirus?, 30.04.2020, https://www.forbes.com/sites/brucelee/2020/04/30/what-do-testicles-have-to-do-with-covid-19-coronavirus/#3c4037691690 (17.05.2020)
- Gautret P., Raoult D. i wsp.: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. DOI: 10.1016/j.ijantimicag.2020.105949 (2020)
- GenBank: Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome, 18.03.2020, https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3 (17.05.2020)
- Gliński Z., Ciołek J.: Nietoperze rezerwuarami i wektorami wirusów chorobotwórczych dla człowieka i zwierząt. Życie Weterynaryjne, 95, 11–16 (2020)
- Grain J., Flanigan T. i wsp.: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 382, 2327–2336 (2020)
- Guan Y., Poon L.L. i wsp.: Isolation and character ization of viruses related to the SARS coronavirus from animals in southern China. Science, 302, 276–278 (2003)
- Guan W.J., Zhong N. i wsp.: Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020)
- Guangdi L., De Clercq E.: Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discovery. 19, 149–150 (2020)
- Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y.: The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak – An Update on the Status. Mil. Med. Res. DOI: 10.1186/s40779-020-00240-0 (2020)
- Han H.J., Wen H.L., Zhou C.M., Chen F.F., Luo L.M., Liu J.W., Yu X.J.: Bats as reservoirs of severe emerging infectious diseases. Virus Res. 205, 1–6 (2015)
- Harmer D., Gilbert M., Bormarn R., Clark K.L.: Quantitative mRNA Expression Profiling of ACE 2, a Novel Homologue of Angiotensin Converting Enzyme. FEBS Lett. 532, 107–110 (2002)
- Harrison C.: Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 38, 379–381 (2020)
- Harvard Health Publishing: Treatments for COVID-19, 24.04. 2020, https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19 (19.05.2020)
- Hoffmann M., Pöhlmann S. i wsp.: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271–280 (2020)
- Holshue M.L., Pillai S.K. i wsp.: First Case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med. 382, 929–936 (2020)
- Horby P.: New data on clinical features, incubation period, and case fatality rate of SARS in Hong Kong and Canada. Euro Surveill. 7, DOI: 10.2807/esw.07.19.02223-en (2003)
- Huang C., Cao B. i wsp.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497–506 (2020)
- Imai Y., Penninger J.M. i wsp.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436, 112–116 (2005)
- Kampf G., Todt D., Pfaender S., Steinmann E.: Persistence of coronavirus on inanimate surfaces and their inactivation with biocidal agents, J. Hosp. Infect. 3, 246–251 (2020)
- Kosobudzki M., Bortkiewicz A.: Genetyczne uwarunkowania chorób układu krążenia. Forum Medycyny Rodzinnej, 6, 1–13 (2012)
- Kuba K., Penninger J.M. i wsp.: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine, 11, 875–879 (2005)
- Lai M.M.C., Holmes K.V.: Coronaviridae and their replication (w) In Fields Virology, red. D.M. Knipe, P.M. Howley, Lippincott Williams & Wilkins, Philadelphia, 2001, s. 1163–1185
- Leung J.M., Yang C.X., Tam A., Shaipanich T., Hackett T.L., Singhera G.K., Dorscheid D.R., Sin D.D.: ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19. Eur. Respir. J. DOI: 10.1183/13993003.00688-2020 (2020)
- Li F.: Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3, 237–261 (2016)
- Liu S., Chan T.C., Chu Y.T., Wu J.T.S., Geng X., Zhao N., Cheng W., Chen E., King C.C.: Comparative epidemiology of human infections with Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Coronaviruses among healthcare personnel. PLoS One, DOI: 10.1371/journal.pone.0149988 (2016)
- Liu S., Jiang S. i wsp.: Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, 363, 938–947 (2004)
- Lokugamage K.G., Narayanan K., Nakagawa K., Terasaki K., Ramirez S.I., Tseng C.K., Makino S.: Middle East Respiratory Syndrome Coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin. J. Virol. 89, 10970–10981 (2015)
- Lu L., Jiang S. i wsp.: Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014)
- Lui P.Y., Wong L.Y.R., Fung C.L., Siu K.L., Yeung M.L., Yuen K.S., Chan C.P., Woo P.C.Y., Yuen K.Y., Jin D.Y.: Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerging Microbes Infect. 5, 1–9 (2016)
- Lundin A., Trybala E. i wsp.: Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus. PLoS Pathog. DOI: 10.1371/journal.ppat.1004166 (2014)
- Ma L., Xie W., Li D., Shi L., Mao Y., Xiong Y., Zhang Y., Zhang M.: Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study. medRxiv, DOI: 10.1101/2020.03.21.20037267 (2020)
- Mahase E.: Covid-19: what do we know so far about a vaccine? BMJ, DOI: 10.1136/bmj.m1679 (2020)
- Marczyńska M.: Zalecenia terapeutyczne dla dzieci zakażonych HIV. HIV & AIDS Review, 12, 116–118 (2013)
- Medicover: Sposoby walki z COVID-19 – leki, osocze rekonwalescencyjne, a może szczepionka?, 19.05.2020, https://www.medicover.pl/o-zdrowiu/sposoby-walki-z-covid-19-lekiosocze-rekonwalescencyjne-a-moze-szczepionka,6916,n,192 (21.05.2020)
- Międzynarodowa Federacja Farmaceutyczna: COVID-19: Informacje kliniczne i wytyczne dotyczące leczenia, 26.03.2020, https://www.nia.org.pl/wp-content/uploads/2020/04/FIP-Przewodnik-COVID-19-PL-002.pdf (18.05.2020)
- Mousavizadeh L., Ghasemi S.: Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection, DOI: 10.1016/j.jmii.2020.03.022 (2020)
- Mrukowicz J., Ściubisz M.: Wyścig po szczepionkę przeciwko SARS-CoV-2. Wielkie nadzieje i wielkie znaki zapytania. Med. Prakt. 5, 36–48 (2020)
- Nejm Journal Watch: Lack of Efficacy of Hydroxychloroquine or Azithromycin on COVID-19 Clinical Course, https://www.jwatch.org/na51549/2020/05/13/lack-efficacy-hydroxychloroquine-or-azithromycin-covid-19 (07.06.2020)
- Nextstrain: Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan using data generated by the Shanghai Public Health Clinical Center & School of Public Health, the National Institute for Viral Disease Control and Prevention, the Institute of Pathogen Biology, and the Wuhan Institute of Virology shared via GISAID, 26.02.2020, https://nextstrain.org/groups/blab/sars-like-cov (17.05.2020)
- Puls Medycyny: Leki na koronawirusa SZAR-CoV-2: skuteczne mogą być już znane substancje, 23.03.2020, https://pulsmedycyny.pl/leki-na-koronawirusa-sars-cov-2-skuteczne-moga-bycjuz-znane-substancje-984865 (09.06.2020)
- Pyrć K.: Ludzkie koronawirusy. Post. Nauk Med. 28, 48–54 (2015)
- Qin N., Kaijin X. i wsp.: Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia. Chinese Journal of Clinical Infectious Diseases, DOI: 10.3760/cma.j.cn115673-20200225-00072 (2020)
- Rastawicki W., Rokosz-Chudziak N.: Charakterystyka oraz ocena przydatności serologicznych testów w diagnostyce zakażeń wywołanych przez koronawirus SARS-CoV-2 na podstawie dostępnych danych producentów i przeglądu piśmiennictwa. Przegl. Epidemiol. 74, 113–132 (2020)
- Reuters: Poland reports first coronavirus case – health minister, 4.03.2020, https://www.reuters.com/article/us-health-coronavirus-poland/poland-reports-first-coronavirus-case-health-minister-idUSKBN20R0U7 (05.06.2020)
- Rut W., Groborz K., Zhang L., Sun X., Zmudzinski M., Hilgenfeld R., Drag M.: Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design. bioRxiv, DOI: 10.1101/2020.03.07.981928 (2020)
- Sama I.E., Voors A.A. i wsp.: Circulating Plasma Concentrations of Angiotensin-Converting Enzyme 2 in Men and Women With Heart Failure and Effects of Renin-Angiotensin-Aldosterone Inhibitors. Eur. Heart J. 41, 1810–1817 (2020)
- Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B.: Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A Review. JAMA, 323, 1824–1836 (2020)
- Sheahan T.P., Baric R.S. i wsp.: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. DOI: 10.1126/scitranslmed.aal3653 (2017)
- Sheahan T.P., Baric R.S. i wsp.: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. DOI: 10.1038/s41467-019-13940-6
- Soro-Paavonen A., Gordin D., Forsblom C., Rosengard-Barlund M., Waden J., Thorn L., Sandholm N., Thomas M.C., Groop P.H., FinnDiane Study Group.: Circulating ACE2 Activity Is Increased in Patients With Type 1 Diabetes and Vascular Complications. J. Hypertens. 30, 375–383 (2012)
- Stilhano R.S., Costa A.J., Nishino M.A., Shams S., Bartolomeo C.S., Breithaupt-Faloppa A.C., Silva E.A., Ramirez A.L., Prado C.M., Ureshino R.P.: SARS-CoV-2 and the Possible Connection to ERs, ACE2 and RAGE: Focus on Susceptibility Factors. Preprints, DOI: 10.20944/preprints202005.0178.v1 (2020)
- Tang X., Lu J. i wsp.: On the orgin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 7, 1012–1023 (2020)
- Tu C., Wang L.F. i wsp.: Antibodies to SARS coro navirus in civets. Emerging Infect. Dis. 10, 2244–2248 (2004)
- Vabret A., Dina J., Brison E., Brouard J., Freymuth F.: Human coronaviruses. Pathol. Biol. (Paris) 57, 149–160 (2009)
- van der Hoek L., Pyrć K., Berkhout B.: Human coronavirus NL63, a new respiratory virus. FEMS Microbiol. Rev. 30, 760–773 (2006)
- van Doremalen N., Munster V.J. i wsp.: Aerosol and Surface Stability of SARS-CoV-2 as Compared With SARS-Cov-1. N. Engl. J. Med. 382, 1564–1567 (2020)
- Vashist S.K.: In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics, DOI: 10.3390/disgnostics10040202 (2020)
- Vijaykrishna D., Smith G.J.D., Zhang J.X., Peiris J.S.M., Chen H., Guan Y.: Evolutionary insights into the ecology of coronaviruses. J. Virol. 81, 4012–4020 (2007)
- Villar J., Gonzales-Martin J.M. i wsp.: Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 8, 267–276 (2020)
- Waliszewski K., Słomski R., Jura J., Oszkinis G., Gabriel M., Strauss E., Pawlak A.: Zmiany częstości alleli i rozkładu genotypów genu ACE w populacji chorych na tętniaka aorty brzusznej. J. Med. Sci. 12, 169–175 (2003)
- Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)
- Wang N., Shang J., Jiang S., Du L.: Subunit Vaccines Against Emering Pathogenic Human Coronaviruses. Front. Mikrobiol. DOI: 10.3389/fmicb.2020.00298 (2020)
- Wang Q., Wong G., Lu G., Yan J., Gao G.F.L.: MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res. 133, 165–177 (2016)
- World Health Organization: Coronavirus diseae (COVID-19) Pandemic, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (16.05.2020)
- World Health Organization: Director-General’s opening remarks at the media briefing on COVID-19, 11.03.2020, https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020 (16.05.2020)
- World Health Organization: Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases, 2.03.2020, https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&i-sAllowed=y, (17.05.2020)
- World Health Organization: Middle East respiratory syndrome coronavirus (MERS-CoV). Summary of current situation, literature update and risk assessment. 07.07.2015, http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf (16.05.2020)
- World Health Organization: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, 31.12.2003, https://www.who.int/csr/sars/country/table2004_04_21/en// (16.05.2020)
- Worldometer: COVID-19 Coronavirus pandemic, 19.05.2020, https://www.worldometers.info/coronavirus (20.05.2020)
- Wu D., Yang X.O.: TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 53, 368–370 (2020)
- Wysocki J., Gonzales-Pacheco F.R., Battle D.: Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports, 10, 70–77 (2008)
- Xiao F., Hiremath S., Knoll G., Zimpelmann J., Srivaratharajah K., Jadhav D., Fergusson D., Kennedy C.R., Burns K.D.: Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One, DOI: 10.1371/journal.pone.0037649 (2012)
- Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H.: Evidence for gastrointensinal infection of SARS-CoV-2. Gastroenterology, 158, 1831–1833 (2020)
- Xinhuanet: New-type coronavirus causes pneumonia in Wuhan: expert, 09.01.2020, http://www.xinhuanet.com/english/2020-01/09/c_138690570.htm (16.05.2020)
- Zhang H., Li H.B., Lyu J.R., Lei X.M., Li W., Wu G., Lyu J., Dai Z.M.: Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 96, 19–24 (2020)
- Zhou P., Shi Z.L. i wsp.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270–273 (2020)
- Zhu N., Tan W. i wsp.: A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020)